Zilxi Generic: When Will Generic Minocycline Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Zilxi Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? April 2027 About 6 months away Why then?
- Has the FDA approved a generic? Not yet None in the FDA’s records yet Why not yet?
- When does the last patent end? October 2030 10 patents listed with the FDA Why is a generic expected sooner?
- Can you buy a generic today? Not yet No company lists one for sale
Generic minocycline is expected to be available in April 2027, about 6 months away. None is for sale yet.
Why April 2027?
The brand company and a generic maker settled their patent fight and agreed on when a generic can launch. It is too early to rate how firm that is.
If Zilxi’s last patent runs to October 2030, how can a generic come sooner?
The 10 patents that run past the expected month, to October 2030 (8,865,139, 8,945,516, 8,992,896, 9,675,700 and 6 more), cover the product’s formulation and a way of using it. A patent like that protects one way of making or using the medicine, not the medicine itself. A generic company can often make its version a different way or leave that use off its label, or a court can rule the patent invalid or not infringed. Here, a settlement between the companies sets the date. Generic companies have been challenging Zilxi’s patents with the FDA since February 2022. That is why the expected month comes before the last protection ends. See the road to a generic
Why hasn’t the FDA approved a generic yet?
That is normal before a launch. The FDA usually can’t give a generic its final approval while a patent or exclusivity still blocks it, so final approval often comes close to the day the generic can be sold. No company holds a “tentative” approval yet either (the FDA’s word for a generic that is ready but still blocked).
Will the generic cost less?
Usually, but no company is recorded as having applied to make one yet, and a single company usually brings only a modest drop. See the price pattern
What should I do now?
Keep taking Zilxi as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Zilxi by the Numbers
- Reason
- Settlement between companiesThe brand company and a generic maker settled their patent fight and agreed on when a generic can launch.
- How sure
- Not rated Too early to rate. The month is where the records point today.
- Price competition
- None filed yet No filers on record
- Brand sales
- under $10M a yearSmall seller
- FDA approved 2020 May 2020 FDA Orange Book
- Patents listed 10 last runs to October 2030 A generic is expected sooner, in April 2027. See why FDA Orange Book
- Medicare Part D spent $144.6K in 2025, for 162 people CMS Part D Spending by Drug
Zilxi’s Road to a Generic
Zilxi has had the market to itself since the FDA approved it in May 2020 (Journey Medical Corp). Its 10 listed patents run to October 2030. Generic companies have challenged its patents with the FDA since February 2022.
The first generic of Zilxi is expected in April 2027.
Why that month: the brand company and a generic maker settled their patent fight and agreed on when a generic can launch. That is about 3.5 years before the last listed patent runs out, in October 2030.
Why a Generic Can Come Before October 2030
The last listed patent runs to October 2030, but it covers the product’s formulation and a way of using it, not the medicine itself, which a generic can often work around or challenge. Dr. Brian explains
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Zilxi Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Zilxi’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 8,865,139 | The product’s formulation; a way of using it (U-1631) | October 2030 | Active |
| 8,945,516 | The product’s formulation | October 2030 | Active |
| 8,992,896 | The product’s formulation; a way of using it (U-1631) | October 2030 | Active |
| 9,675,700 | The product’s formulation; a way of using it (U-1631) | October 2030 | Active |
| 10,213,512 | The product’s formulation; a way of using it (U-1631) | October 2030 | Active |
| 10,265,404 | The product’s formulation | October 2030 | Active |
| 10,322,186 | A way of using it (U-1631) | October 2030 | Active |
| 10,946,101 | A way of using it (U-1631) | October 2030 | Active |
| 12,138,311 | A way of using it (U-1631) | October 2030 | Active |
| 12,661,407 | A way of using it (U-1631) | October 2030 | Active |
Source: FDA Orange Book, application 213690. Patent numbers open the patent on Google Patents.
Patent Challenges to Zilxi
The first patent challenge to Zilxi reached the FDA in February 2022, from one company on that first day. The FDA has not approved a first challenger’s generic yet.
What Is a Patent Challenge?
A generic company that wants to sell its version before Zilxi’s patents run out can tell the FDA that a patent is invalid, or that its version does not infringe it. The FDA calls this a “Paragraph IV certification.” The brand company usually sues, and the FDA then generally cannot approve that generic for up to 30 months while the case runs. To reward going first, the companies that challenge first can get a 180-day head start: the FDA cannot approve the generics that came after them until it ends.
| Product | First challenged | Companies that day | 180-day head start | First challenger’s generic | Challenged patents run to | |
|---|---|---|---|---|---|---|
| Approved | On sale | |||||
| Topical aerosol foam, 0.015 | February 2022 | 1 company | Head start no longer applies decided December 2025 | Not yet | Not yet | October 2030 |
Source: the FDA’s Paragraph IV Patent Certifications list, as of September 2026. The FDA began posting the 180-day decisions and the first challenger’s approval and first sale in June 2019: an older entry it has not updated since reads “Not posted”, and “Not yet” means the list records no such event. “Companies that day” is the FDA’s count of challenges that arrived on the first day.
Who Is Lined Up to Make Generic Minocycline
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No company is recorded as having applied to the FDA to make a generic Zilxi yet.
Generic companies have challenged Zilxi’s patents with the FDA since February 2022: see the patent challenges.
Approved by the FDA
Not yet. The FDA has not approved a generic minocycline. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Not yet. No company lists a generic minocycline for sale with the FDA.
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Zilxi Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Zilxi, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Zilxi
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Zilxi, before manufacturer rebates.
- $62.8K
- January to March 2026, the latest CMS has posted
For 98 people, about $519 per prescription fill - $144.6K
- 2025, the whole year
For 162 people, about $502 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $62,844 | 98 | $519.37 |
| 2025 | $144,576 | 162 | $502.00 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Zilxi only, so no generic is counted in it. What CMS says it is used for: This medication is used to treat acne or rosacea. Minocycline belongs to a class of drugs known as tetracycline antibiotics.
Zilxi Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| EQ 1.5% BASE | Aerosol, foam | Topical | May 2020 | Prescription reference product |
Source: FDA Orange Book, Journey Medical Corp. Listed for sale today by Journey Medical Corporation (FDA NDC Directory).
Zilxi NDC Codes and Packages
Each Zilxi package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 72356-0103-03 | 15 mg/g aerosol, foam | can of 30 g | Journey Medical Corporation |
| 69489-0212-03 | MINOCYCLINE HYDROCHLORIDE 15 mg/g aerosol, foam | can of 3 g | Journey Medical Corporation |
| 69489-0212-07 | MINOCYCLINE HYDROCHLORIDE 15 mg/g aerosol, foam | can of 7 g | Journey Medical Corporation |
| 69489-0212-30 | MINOCYCLINE HYDROCHLORIDE 15 mg/g aerosol, foam | can of 30 g | Journey Medical Corporation |
| 69489-0212-30 | MINOCYCLINE HYDROCHLORIDE 15 mg/g aerosol, foam | can of 30 g | Journey Medical Corporation |
Source: the FDA NDC Directory, current listings only. Only packages sold under Zilxi’s own FDA approval (NDA 213690) are listed, never a generic. Some codes belong to companies that repackage Zilxi: it is the same medicine in a different package.
What a Generic Zilxi Means for You
Nothing Changes Until It Is in Pharmacies
Until a generic is actually for sale, keep filling Zilxi as usual. When one arrives, there is nothing you need to sign up for.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Zilxi”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.
Questions people ask about Zilxi
Is there a generic for Zilxi right now?
No. As of October 9, 2026 no generic minocycline is listed for sale in the FDA NDC Directory.
When will Zilxi go generic?
April 2027 is the expected month. The brand company and a generic maker settled their patent fight and agreed on when a generic can launch. The last listed patent runs to October 2030, but it covers the product’s formulation and a way of using it, not the medicine itself, which a generic can often work around or challenge.
Will generic minocycline be the same as Zilxi?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. No company is recorded as having applied to the FDA to make one yet, and a single company usually brings only a modest drop.
Has the FDA approved a generic Zilxi?
Not yet. The FDA Orange Book lists no approved generic version of Zilxi.
When does the Zilxi patent expire?
The FDA Orange Book lists 10 patents for Zilxi; the last runs to October 2030. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (April 2027) weighs all of that.
Has anyone challenged the Zilxi patents?
Yes. The first patent challenge to Zilxi reached the FDA in February 2022, from one company on that first day. The FDA has not approved a first challenger’s generic yet. A patent challenge (a “Paragraph IV certification”) is a generic company telling the FDA that a patent listed for the brand is invalid or will not be infringed by its version. The first companies to file one can earn a 180-day head start, during which the FDA cannot approve the generics that filed after them.
Changes to This Projection
- First generic expected April 2027 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- VyndaqelTafamidis MeglumineJuly to December 2028
- SpravatoEsketamine Hydrochloride2031 to 2032
- EmrosiMinocycline Hydrochloride2035 to 2036
- OpfoldaMiglustatAugust 2037
- JournavxSuzetrigineDecember 2040
- AsteproAzelastine HydrochlorideTBD no date yet
About Zilxi
- Generic name minocycline
- How it is taken On the skin
- Company Journey Medical Corp
- Hard to copy Inhalers, injectables, patches and other hard-to-copy products. Fewer companies attempt them and dates slip more often.
- Patent challenges Since February 2022 (FDA)
- More drugs Brand-name drugs starting with Z
- Have a question? A pharmacist answers, free. Ask about Zilxi
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, FDA Paragraph IV Patent Certifications list, CMS Medicare Part D Spending by Drug, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.